-
Elections Officials Battle a Deluge of Disinformation
County clerks and secretaries of state are overwhelmed this year, as they stare down a “perpetual moving target” of new conspiracy theories, political pressure and threats.
-
Private REITS Were a Hot Investment Trend, but They’ve Lost Some Appeal
Drawn by the opportunity to invest with private equity firms, small investors rushed into real estate investment trusts. But the funds have lost some appeal as interest rates have climbed.
-
When Olympic Sponsors Go Rogue
LVMH and Samsung intruded on previously sacrosanct spaces at the Paris Games, angering fellow sponsors and raising concerns about a repeat at the closing ceremony.
-
How to Upgrade Your MovieWatching Experience at Home
As technology continues to advance, the way we consume entertainment has drastically changed. Gone are the days of waiting in long lines at the movie theater or renting VHS tapes from the local store. With streaming services and high-quality home theater systems, it’s now possible to have a movie-watching experience right in the comfort of…
-
EU AI Act: Key Points for Financial Services Businesses
The European Union (EU) Artificial Intelligence Act (AI Act), Regulation (EU) 2024/1689 of the European Parliament and of the Council of 13 June 2024 laying down harmonised rules on artificial intelligence and amending Regulations (EC) No 300/2008, (EU) No 167/2013, (EU) No 168/2013, (EU) 2018/858, (EU) 2018/1139 and (EU) 2019/2144 and Directives 2014/90/EU, (EU) 2016/797…
-
FDA Rejects Application for Psychedelic Drug
The U.S. Food and Drug Administration (FDA or Agency) rejected the new drug application (NDA) for a drug marketing approval submitted by Lykos Therapeutics Inc. (Lykos) for its psychedelic MDMA drug on Aug. 9, 2024. Lykos submitted the application to secure FDA approval for use of the drug to treat post-traumatic stress disorder (PTSD). No……By:…
-
The Risks of Unregulated Regenerative Medicine
A recent New York Times article reported that dozens of spine surgery patients at NewYork-Presbyterian/Weill Cornell Medical Center were treated with a product that was not approved for use in such procedures. Burst Biologics, Inc., the manufacturer of BioBurst, a stem cell treatment derived from umbilical cord blood, was issued a warning letter by the U.S. Food and Drug Administration…
-
Spotlight On: Biosimilar Litigations – August 2024
Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference product sponsors as well as litigations between two biosimilar applicants/manufacturers are included. Litigations relating to disputes between two reference product sponsors, or non-practicing entities/universities and reference product sponsors are not included. Litigations related solely to manufacturing…By: Venable…
-
Governor Pritzker Signs Amendment Limiting Damages To A Single Recovery
Earlier this year, we reported that the Illinois Senate passed Senate Bill 2979 with a vote of 46 to 13, and the Illinois House of Representatives passed Senate Bill 2979 with a vote 81 to 30. This bill addressed concerns arising from recent legal interpretations of the Illinois Biometric Information Privacy Act (“BIPA,” 740 ILCS…
-
Educators Benefit Consultants d/b/a Aviben Provides Notice of Recent Data Breach
On August 6, 2024, Educators Benefit Consultants, LLC d/b/a Aviben (“Aviben”) filed a notice of data breach with the Attorney General of Maine after discovering that an unauthorized party was able to access portions of its computer network. In this notice, Aviben explains that the incident resulted in an unauthorized party being able to access…
